Related Research Articles
Neurosurgery or neurological surgery, known in common parlance as brain surgery, is the medical specialty concerned with the surgical treatment of disorders which affect any portion of the nervous system including the brain, spinal cord and peripheral nervous system.
A brain–computer interface (BCI), sometimes called a brain–machine interface (BMI), is a direct communication link between the brain's electrical activity and an external device, most commonly a computer or robotic limb. BCIs are often directed at researching, mapping, assisting, augmenting, or repairing human cognitive or sensory-motor functions. They are often conceptualized as a human–machine interface that skips the intermediary of moving body parts (hands...), although they also raise the possibility of erasing the distinction between brain and machine. BCI implementations range from non-invasive and partially invasive to invasive, based on how physically close electrodes are to brain tissue.
BrainGate is a brain implant system, currently under development and in clinical trials, designed to help those who have lost control of their limbs, or other bodily functions, such as patients with amyotrophic lateral sclerosis (ALS) or spinal cord injury. The Braingate technology and related Cyberkinetic’s assets are now owned by privately held Braingate, Co. The sensor, which is implanted into the brain, monitors brain activity in the patient and converts the intention of the user into computer commands.
Matthew Nagle was the first person to use a brain–computer interface to restore functionality lost due to paralysis. He was a C3 tetraplegic, paralyzed from the neck down after being stabbed.
Brain implants, often referred to as neural implants, are technological devices that connect directly to a biological subject's brain – usually placed on the surface of the brain, or attached to the brain's cortex. A common purpose of modern brain implants and the focus of much current research is establishing a biomedical prosthesis circumventing areas in the brain that have become dysfunctional after a stroke or other head injuries. This includes sensory substitution, e.g., in vision. Other brain implants are used in animal experiments simply to record brain activity for scientific reasons. Some brain implants involve creating interfaces between neural systems and computer chips. This work is part of a wider research field called brain–computer interfaces.
Neuroprosthetics is a discipline related to neuroscience and biomedical engineering concerned with developing neural prostheses. They are sometimes contrasted with a brain–computer interface, which connects the brain to a computer rather than a device meant to replace missing biological functionality.
A spinal cord stimulator (SCS) or dorsal column stimulator (DCS) is a type of implantable neuromodulation device that is used to send electrical signals to select areas of the spinal cord for the treatment of certain pain conditions. SCS is a consideration for people who have a pain condition that has not responded to more conservative therapy. There are also spinal cord stimulators under research and development that could enable patients with spinal cord injury to walk again via epidural electrical stimulation (EES).
A human microchip implant is any electronic device implanted subcutaneously (subdermally) usually via an injection. Examples include an identifying integrated circuit RFID device encased in silicate glass which is implanted in the body of a human being. This type of subdermal implant usually contains a unique ID number that can be linked to information contained in an external database, such as identity document, criminal record, medical history, medications, address book, and other potential uses.
The neurotrophic electrode is an intracortical device designed to read the electrical signals that the brain uses to process information. It consists of a small, hollow glass cone attached to several electrically conductive gold wires. The term neurotrophic means "relating to the nutrition and maintenance of nerve tissue" and the device gets its name from the fact that it is coated with Matrigel and nerve growth factor to encourage the expansion of neurites through its tip. It was invented by neurologist Dr. Philip Kennedy and was successfully implanted for the first time in a human patient in 1996 by neurosurgeon Roy Bakay.
Brain technology, or self-learning know-how systems, defines a technology that employs latest findings in neuroscience. [see also neuro implants] The term was first introduced by the Artificial Intelligence Laboratory in Zurich, Switzerland, in the context of the Roboy project. Brain Technology can be employed in robots, know-how management systems and any other application with self-learning capabilities. In particular, Brain Technology applications allow the visualization of the underlying learning architecture often coined as "know-how maps".
Neuromodulation is "the alteration of nerve activity through targeted delivery of a stimulus, such as electrical stimulation or chemical agents, to specific neurological sites in the body". It is carried out to normalize – or modulate – nervous tissue function. Neuromodulation is an evolving therapy that can involve a range of electromagnetic stimuli such as a magnetic field (rTMS), an electric current, or a drug instilled directly in the subdural space. Emerging applications involve targeted introduction of genes or gene regulators and light (optogenetics), and by 2014, these had been at minimum demonstrated in mammalian models, or first-in-human data had been acquired. The most clinical experience has been with electrical stimulation.
Spinal cord injury research seeks new ways to cure or treat spinal cord injury in order to lessen the debilitating effects of the injury in the short or long term. There is no cure for SCI, and current treatments are mostly focused on spinal cord injury rehabilitation and management of the secondary effects of the condition. Two major areas of research include neuroprotection, ways to prevent damage to cells caused by biological processes that take place in the body after the injury, and neuroregeneration, regrowing or replacing damaged neural circuits.
Stentrode is a small stent-mounted electrode array permanently implanted into a blood vessel in the brain, without the need for open brain surgery. It is in clinical trials as a brain–computer interface (BCI) for people with paralyzed or missing limbs, who will use their neural signals or thoughts to control external devices, which currently include computer operating systems. The device may ultimately be used to control powered exoskeletons, robotic prosthesis, computers or other devices.
Neuralink Corp. is an American neurotechnology company that has developed, as of 2024, implantable brain–computer interfaces (BCIs). It was founded by Elon Musk and a team of seven scientists and engineers. Neuralink was launched in 2016 and was first publicly reported in March 2017. The company is based in Fremont, California with plans to build a three-story building with office and manufacturing space near Austin, Texas in Del Valle, located about 10 miles east of Tesla's headquarters and manufacturing plant that opened in 2022.
Ali R. Rezai is an Iranian-born American neurosurgeon and neuroscientist. His work and research has focused on neuromodulation treatments for patients with neurological and mental health conditions, including neuromodulation techniques such as deep brain stimulation (DBS) through brain chip implants to treat Parkinson's disease tremors, obsessive–compulsive disorder, Alzheimer's disease, traumatic brain injury, spinal cord injury, and addiction. Recent research since 2020 has focused on deep brain stimulation for addiction treatment, as well as focused ultrasound to treat tremor, addiction and Alzheimer's disease.
Shivon Alice Zilis is a Canadian technology executive and venture capitalist.
Precision Neuroscience is an American brain–computer interface (BCI) company based in New York City and with offices in Mountain View, California, Addison, Texas and Minneapolis, Minnesota.
Walk Again Project is an international, non-profit consortium led by Miguel Nicolelis, created in 2009 in a partnership between Duke University and the IINN/ELS, where researchers come together to find neuro-rehabilitation treatments for spinal cord injuries, which pioneered the development and use of the brain–machine interface, including its non-invasive version, with an EEG.
Blindsight is an experimental medical device developed by Neuralink. It has received Breakthrough Device Designation from the US Food and Drugs Administration (FDA).
Paradromics is an American brain–computer interface (BCI) company headquartered in Austin, Texas with a second office located in Oakland, California.
References
- 1 2 Vance, Ashlee (May 16, 2024). "Neuralink's First Patient: 'It Blows My Mind So Much'". Bloomberg Businessweek .
- 1 2 Sepulveda, Laura Daniella; Slade, Shelby (March 21, 2024). "Arizona native Noland Arbaugh is first Neuralink patient: what to know". Arizona Republic . Retrieved May 8, 2024.
- ↑ "Elon Musk's Neuralink implants brain chip in first human". Reuters . January 30, 2024. Retrieved October 21, 2024.
- ↑ "Neuralink's brain chip encounters issues post surgery, says Elon Musk's company". Times of India . May 9, 2024. Retrieved May 8, 2024.
- ↑ "Elon Musk's Neuralink responds to 'Brain-Implant' malfunction, implications for FDA approval and future trials". LiveMint . May 9, 2024. Retrieved May 8, 2024.
- ↑ Al-Arshani, Sarah (March 22, 2024). "Video shows first Neuralink brain chip patient playing chess by moving cursor with thoughts". USA Today . Retrieved May 9, 2024.
- ↑ Winkler, Rolf (May 20, 2024). "Elon Musk's Neuralink Gets FDA Green Light for Second Patient, as First Describes His Emotional Journey". Wall Street Journal . Retrieved May 20, 2024.